MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo …